uniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (IST...
June 21 2019 - 7:00AM
uniQure Announces Presentations at the Upcoming 27th Congress of
the International Society on Thrombosis and Haemostasis (ISTH)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that five data presentations, of which three
are oral presentations, will be featured at the upcoming 27th
congress of the International Society on Thrombosis and Haemostasis
(ISTH), taking place in Melbourne, Australia from July 6 – 10,
2019.
"The data to be presented at ISTH showcase our
gene therapy expertise in hemophilia B with both long-term safety
and durability from our ongoing Phase 1-2 study of AMT-060 , and up
to 9 months of safety and FIX activity in the Phase IIb
dose-confirmation study of AMT-061,” stated Matt Kapusta, chief
executive officer at uniQure. “We also are very pleased to have an
oral presentation on our novel gene therapy approach to treat
hemophilia A and look forward to presenting these data at the
conference.”
Specific details on uniQure’s presentations at
ISTH include:
- Title: AMT-061 (AAV5-Padhua hFIX variant) an
Enhanced Vector for Gene Transfer in Adults with Severe or
Moderate-Severe Hemophilia B: Follow-up up to 9 Months in a Phase
2b Trial (OC 01.1) Oral Session Title: Gene
Therapy Clinical I Date and Time: Saturday
July 6, 1:00 – 1:15 p.m. AEST/ Friday July 5, 11:00 p.m.
ET Location: Melbourne Room 2
- Title: Stable Expression of FIX and Maintained
Reductions in Bleeding and Factor IX Consumption Following AMT-060
Gene Therapy with up to 3.5 Years of Follow-up in Adults with
Severe or Moderate-Severe Hemophilia B (OC 01.4) Oral
Session Title: Gene Therapy Clinical I Date
and Time: Saturday July 6, 1:45 – 2:00 p.m. AEST/ Friday
July 5, 11:45 p.m. ET Location: Melbourne
Room 2
- Title: AAV5-mediated Gene Therapy for
Hemophilia A with Factor IX Variant that Functions Independently of
FVIII (OC 22.3) Oral session title: Gene
Therapy Basic I Date and Time: Sunday July 7,
3:15 – 3:30 p.m. AEST/ Sunday July 7, 01:15 a.m.
ET Location: Melbourne Room 1
- Title: No Evidence of Germline Transmission of
Vector DNA Following Intravenous Administration of AAV5-hFIX to
Male Mice (PB 0303) Poster Date and Time:
Sunday, July 7, 6:30 – 7:30 p.m. AEST/ Sunday July 7, 4:30 a.m.
ET Location: Exhibition Hall
- Title: Low Predicted Immunogenicity Risk
Associated with FIX Variants that can Promote Coagulation in the
Absence of FVIII: in vitro and in silico assessments (PB
0301) Poster Date and Time: Sunday, July 7,
6:30 – 7:30 p.m. AEST/ Sunday July 7, 4:30 a.m.
ET Location: Exhibition Hall
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary and partnered gene therapies to treat patients with
hemophilia, Huntington’s disease and other severe genetic diseases.
www.uniQure.com
uniQure Contacts:
FOR INVESTORS: |
|
|
|
FOR MEDIA: |
|
|
Maria E. Cantor |
|
Eva M. Mulder |
|
Tom Malone |
Direct: 339-970-7536 |
|
Direct: +31 20 240 6103 |
|
Direct: 339-970-7558 |
Mobile: 617-680-9452 |
|
Mobile: +31 6 52 33 15 79 |
|
Mobile:339-223-8541 |
m.cantor@uniQure.com |
|
e.mulder@uniQure.com |
|
t.malone@uniQure.com |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2024 to Apr 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2023 to Apr 2024